New UN Program Hopes to Begin Large-Scale Trials of AIDS Vaccines in 1996

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 1
Volume 4
Issue 1

GENEVA, Switzerland--A newly established United Nations AIDS program based in Geneva has announced plans to initiate large-scale clinical trials of two HIV vaccines as early as mid-1996, probably in Brazil and Thailand. Dr. Peter Piot, chief of research at the World Health Organization's Global Program on AIDS, will head the new group, which will involve six UN agencies.

GENEVA, Switzerland--A newly established United Nations AIDS programbased in Geneva has announced plans to initiate large-scale clinicaltrials of two HIV vaccines as early as mid-1996, probably in Braziland Thailand. Dr. Peter Piot, chief of research at the World HealthOrganization's Global Program on AIDS, will head the new group,which will involve six UN agencies.

From 3,000 to 20,000 volunteers will participate in the trialsin the two developing countries, Dr. Piot said. The UN group plansto conduct behavioral research and pilot studies in an effortto ensure that volunteers do not engage in risky behavior duringthe trial because they think the vaccine is protecting them.

Last October, a WHO advisory committee recommended that the organizationgo ahead with plans for large-scale HIV vaccine trials. Such trialswere rejected last June by a US panel.

With an estimated 17 million people infected worldwide, even avaccine with a low degree of efficacy would prove valuable instemming the epidemic, the WHO advisory committee argued.

Recent Videos
Lisa J. States, MD, discussed further steps for improving early detection and screening methods in patients with Li–Fraumeni syndrome.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
9 Experts are featured in this series.
9 Experts are featured in this series.
Additional genetic testing measures and targeted therapies may improve outcomes for patients with diverse molecular subgroups of gastric cancers.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
Related Content